Search Results

Catalent, Inc. announced that, at its Special Meeting of Stockholders held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.

Catalent, Inc. and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.

Novo Nordisk seems to believe it can do a better job managing troubled Catalent than the contract manufacturer. However, the Danish drugmaker has its work cut out for it.

This week, Greg, Heather and Tyler discuss reaction to ⁠Novo Nordisk’s purchase of Catalent⁠ and speculate on what that means for existing manufacturing contracts, customers and consequences with ⁠regulators⁠.

The Federal Trade Commission has asked for an additional 30 days for its review of Novo Nordisk’s $16.5 billion acquisition of Catalent, with the companies expecting to complete the merger by the end of 2024.

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

The FTC and the U.S. Department of Justice’s antitrust division will have another 30 days to examine Novo Nordisk Foundation’s acquisition of contract manufacturer Catalent, according to an SEC filing.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.